Listed

Heron Therapeutics, Inc.

HRTXNasdaqCIK 818033HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$37.7m, Q2 FY2026
Operating income−$2.0m, Q2 FY2026
Net income−$5.5m, Q2 FY2026
Heron Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m31.4Revenue, Q3 FY2023, three months to 2023-09-30$31.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2024-11-12, accession 0000950170-24-124698.Report this figure34.2Revenue, Q4 FY2023, three months to 2023-12-31$34.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure34.7Revenue, Q1 FY2024, three months to 2024-03-31$34.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-05-06, accession 0000950170-25-063971.Report this figure36.0Revenue, Q2 FY2024, three months to 2024-06-30$36.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-08-08, accession 0000950170-25-105475.Report this figure32.8Revenue, Q3 FY2024, three months to 2024-09-30$32.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure40.8Revenue, Q4 FY2024, three months to 2024-12-31$40.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure38.9Revenue, Q1 FY2025, three months to 2025-03-31$38.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure37.2Revenue, Q2 FY2025, three months to 2025-06-30$37.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure38.2Revenue, Q3 FY2025, three months to 2025-09-30$38.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure40.6Revenue, Q4 FY2025, three months to 2025-12-31$40.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure34.7Revenue, Q1 FY2026, three months to 2026-03-31$34.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure37.7Revenue, Q2 FY2026, three months to 2026-06-30$37.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure
Cost of revenue$m18.2Cost of revenue, Q3 FY2023, three months to 2023-09-30$18.2m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2024-11-12, accession 0000950170-24-124698.Report this figure9.9Cost of revenue, Q4 FY2023, three months to 2023-12-31$9.9m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure8.4Cost of revenue, Q1 FY2024, three months to 2024-03-31$8.4m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-05-06, accession 0000950170-25-063971.Report this figure10.5Cost of revenue, Q2 FY2024, three months to 2024-06-30$10.5m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-08-08, accession 0000950170-25-105475.Report this figure9.5Cost of revenue, Q3 FY2024, three months to 2024-09-30$9.5m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure10.2Cost of revenue, Q4 FY2024, three months to 2024-12-31$10.2m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure8.5Cost of revenue, Q1 FY2025, three months to 2025-03-31$8.5m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure9.9Cost of revenue, Q2 FY2025, three months to 2025-06-30$9.9m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure11.9Cost of revenue, Q3 FY2025, three months to 2025-09-30$11.9m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure11.1Cost of revenue, Q4 FY2025, three months to 2025-12-31$11.1m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure10.6Cost of revenue, Q1 FY2026, three months to 2026-03-31$10.6m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure11.6Cost of revenue, Q2 FY2026, three months to 2026-06-30$11.6m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure
Gross profit$m13.2Gross profit, Q3 FY2023, three months to 2023-09-30$13.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2024-11-12, accession 0000950170-24-124698.Report this figure24.3Gross profit, Q4 FY2023, three months to 2023-12-31$24.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure26.2Gross profit, Q1 FY2024, three months to 2024-03-31$26.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-05-06, accession 0000950170-25-063971.Report this figure25.5Gross profit, Q2 FY2024, three months to 2024-06-30$25.5m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-08-08, accession 0000950170-25-105475.Report this figure23.4Gross profit, Q3 FY2024, three months to 2024-09-30$23.4m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure30.6Gross profit, Q4 FY2024, three months to 2024-12-31$30.6m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure30.4Gross profit, Q1 FY2025, three months to 2025-03-31$30.4m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure27.3Gross profit, Q2 FY2025, three months to 2025-06-30$27.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure26.3Gross profit, Q3 FY2025, three months to 2025-09-30$26.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure29.5Gross profit, Q4 FY2025, three months to 2025-12-31$29.5m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure24.1Gross profit, Q1 FY2026, three months to 2026-03-31$24.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure26.1Gross profit, Q2 FY2026, three months to 2026-06-30$26.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure
Research and development$m9.3Research and development, Q3 FY2023, three months to 2023-09-30$9.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0000950170-24-124698.Report this figure7.8Research and development, Q4 FY2023, three months to 2023-12-31$7.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure4.6Research and development, Q1 FY2024, three months to 2024-03-31$4.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-06, accession 0000950170-25-063971.Report this figure4.4Research and development, Q2 FY2024, three months to 2024-06-30$4.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-08, accession 0000950170-25-105475.Report this figure4.5Research and development, Q3 FY2024, three months to 2024-09-30$4.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure3.2Research and development, Q4 FY2024, three months to 2024-12-31$3.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure2.3Research and development, Q1 FY2025, three months to 2025-03-31$2.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure2.9Research and development, Q2 FY2025, three months to 2025-06-30$2.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure3.5Research and development, Q3 FY2025, three months to 2025-09-30$3.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure3.7Research and development, Q4 FY2025, three months to 2025-12-31$3.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure2.4Research and development, Q1 FY2026, three months to 2026-03-31$2.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure2.7Research and development, Q2 FY2026, three months to 2026-06-30$2.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure
Operating income$m(24.9)Operating income, Q3 FY2023, three months to 2023-09-30−$24.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0000950170-24-124698.Report this figure(10.2)Operating income, Q4 FY2023, three months to 2023-12-31−$10.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure(4.8)Operating income, Q1 FY2024, three months to 2024-03-31−$4.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-06, accession 0000950170-25-063971.Report this figure(6.4)Operating income, Q2 FY2024, three months to 2024-06-30−$6.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-08, accession 0000950170-25-105475.Report this figure(4.5)Operating income, Q3 FY2024, three months to 2024-09-30−$4.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure4.2Operating income, Q4 FY2024, three months to 2024-12-31$4.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure3.2Operating income, Q1 FY2025, three months to 2025-03-31$3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure(1.6)Operating income, Q2 FY2025, three months to 2025-06-30−$1.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure(4.1)Operating income, Q3 FY2025, three months to 2025-09-30−$4.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure0.0Operating income, Q4 FY2025, three months to 2025-12-31$38.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure(4.8)Operating income, Q1 FY2026, three months to 2026-03-31−$4.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure(2.0)Operating income, Q2 FY2026, three months to 2026-06-30−$2.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(25.0)Net income, Q3 FY2023, three months to 2023-09-30−$25.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0000950170-24-124698.Report this figure(10.7)Net income, Q4 FY2023, three months to 2023-12-31−$10.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure(3.2)Net income, Q1 FY2024, three months to 2024-03-31−$3.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure(9.2)Net income, Q2 FY2024, three months to 2024-06-30−$9.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure(4.8)Net income, Q3 FY2024, three months to 2024-09-30−$4.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure3.7Net income, Q4 FY2024, three months to 2024-12-31$3.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure2.6Net income, Q1 FY2025, three months to 2025-03-31$2.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure(2.4)Net income, Q2 FY2025, three months to 2025-06-30−$2.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure(17.5)Net income, Q3 FY2025, three months to 2025-09-30−$17.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure(3.0)Net income, Q4 FY2025, three months to 2025-12-31−$3.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure(8.1)Net income, Q1 FY2026, three months to 2026-03-31−$8.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure(5.5)Net income, Q2 FY2026, three months to 2026-06-30−$5.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure
Diluted EPS$ per share(0.17)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0000950170-24-124698.Report this figurenot reported(0.02)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-06, accession 0000950170-25-063971.Report this figure(0.06)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-08, accession 0000950170-25-105475.Report this figure(0.03)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figurenot reported0.01Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure(0.02)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure(0.10)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figurenot reported(0.04)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure(0.03)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure
Basic EPS$ per share(0.17)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.17 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0000950170-24-124698.Report this figurenot reported(0.02)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-06, accession 0000950170-25-063971.Report this figure(0.06)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.06 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-08, accession 0000950170-25-105475.Report this figure(0.03)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figurenot reported0.02Basic EPS, Q1 FY2025, three months to 2025-03-31$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure(0.02)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure(0.10)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figurenot reported(0.04)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.04 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure(0.03)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure

Balance sheet

Cash and equivalents$20.7m, Q2 FY2026
Shareholders' equity$6.9m, Q2 FY2026
Heron Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m34.9Cash and equivalents, Q3 FY2023, at 2023-09-30$34.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-14, accession 0000950170-23-063714.Report this figure28.7Cash and equivalents, FY2023, at 2023-12-31$28.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-27, accession 0000950170-25-028374.Report this figure20.5Cash and equivalents, Q1 FY2024, at 2024-03-31$20.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-07, accession 0000950170-24-053964.Report this figure18.4Cash and equivalents, Q2 FY2024, at 2024-06-30$18.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-06, accession 0000950170-24-091764.Report this figure25.7Cash and equivalents, Q3 FY2024, at 2024-09-30$25.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0000950170-24-124698.Report this figure25.8Cash and equivalents, FY2024, at 2024-12-31$25.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001193125-26-073515.Report this figure19.3Cash and equivalents, Q1 FY2025, at 2025-03-31$19.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-06, accession 0000950170-25-063971.Report this figure16.5Cash and equivalents, Q2 FY2025, at 2025-06-30$16.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-08, accession 0000950170-25-105475.Report this figure43.1Cash and equivalents, Q3 FY2025, at 2025-09-30$43.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure28.6Cash and equivalents, FY2025, at 2025-12-31$28.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure26.1Cash and equivalents, Q1 FY2026, at 2026-03-31$26.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure20.7Cash and equivalents, Q2 FY2026, at 2026-06-30$20.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure
Current assets$m194Current assets, Q3 FY2023, at 2023-09-30$194.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-14, accession 0000950170-23-063714.Report this figure189Current assets, FY2023, at 2023-12-31$188.8m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-27, accession 0000950170-25-028374.Report this figure186Current assets, Q1 FY2024, at 2024-03-31$185.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-07, accession 0000950170-24-053964.Report this figure191Current assets, Q2 FY2024, at 2024-06-30$191.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-06, accession 0000950170-24-091764.Report this figure195Current assets, Q3 FY2024, at 2024-09-30$195.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0000950170-24-124698.Report this figure209Current assets, FY2024, at 2024-12-31$209.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-26, accession 0001193125-26-073515.Report this figure213Current assets, Q1 FY2025, at 2025-03-31$212.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-06, accession 0000950170-25-063971.Report this figure211Current assets, Q2 FY2025, at 2025-06-30$210.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-08, accession 0000950170-25-105475.Report this figure229Current assets, Q3 FY2025, at 2025-09-30$229.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure238Current assets, FY2025, at 2025-12-31$238.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure229Current assets, Q1 FY2026, at 2026-03-31$229.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure230Current assets, Q2 FY2026, at 2026-06-30$229.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure
Total assets$m229Total assets, Q3 FY2023, at 2023-09-30$229.2m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-14, accession 0000950170-23-063714.Report this figure223Total assets, FY2023, at 2023-12-31$222.5m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-27, accession 0000950170-25-028374.Report this figure218Total assets, Q1 FY2024, at 2024-03-31$217.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-07, accession 0000950170-24-053964.Report this figure218Total assets, Q2 FY2024, at 2024-06-30$218.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-06, accession 0000950170-24-091764.Report this figure221Total assets, Q3 FY2024, at 2024-09-30$220.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0000950170-24-124698.Report this figure233Total assets, FY2024, at 2024-12-31$233.1m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-26, accession 0001193125-26-073515.Report this figure236Total assets, Q1 FY2025, at 2025-03-31$235.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-06, accession 0000950170-25-063971.Report this figure232Total assets, Q2 FY2025, at 2025-06-30$232.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-08, accession 0000950170-25-105475.Report this figure249Total assets, Q3 FY2025, at 2025-09-30$248.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure256Total assets, FY2025, at 2025-12-31$255.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure246Total assets, Q1 FY2026, at 2026-03-31$246.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure252Total assets, Q2 FY2026, at 2026-06-30$252.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure
Current liabilities$m79.7Current liabilities, Q3 FY2023, at 2023-09-30$79.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-14, accession 0000950170-23-063714.Report this figure79.7Current liabilities, FY2023, at 2023-12-31$79.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-27, accession 0000950170-25-028374.Report this figure75.4Current liabilities, Q1 FY2024, at 2024-03-31$75.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-07, accession 0000950170-24-053964.Report this figure80.3Current liabilities, Q2 FY2024, at 2024-06-30$80.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-06, accession 0000950170-24-091764.Report this figure85.5Current liabilities, Q3 FY2024, at 2024-09-30$85.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0000950170-24-124698.Report this figure91.5Current liabilities, FY2024, at 2024-12-31$91.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-26, accession 0001193125-26-073515.Report this figure88.6Current liabilities, Q1 FY2025, at 2025-03-31$88.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-06, accession 0000950170-25-063971.Report this figure259Current liabilities, Q2 FY2025, at 2025-06-30$258.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-08, accession 0000950170-25-105475.Report this figure89.7Current liabilities, Q3 FY2025, at 2025-09-30$89.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure96.1Current liabilities, FY2025, at 2025-12-31$96.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure90.5Current liabilities, Q1 FY2026, at 2026-03-31$90.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure92.1Current liabilities, Q2 FY2026, at 2026-06-30$92.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure
Total liabilities$m257Total liabilities, Q3 FY2023, at 2023-09-30$257.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-14, accession 0000950170-23-063714.Report this figure256Total liabilities, FY2023, at 2023-12-31$256.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-27, accession 0000950170-25-028374.Report this figure252Total liabilities, Q1 FY2024, at 2024-03-31$251.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-07, accession 0000950170-24-053964.Report this figure256Total liabilities, Q2 FY2024, at 2024-06-30$256.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-06, accession 0000950170-24-091764.Report this figure261Total liabilities, Q3 FY2024, at 2024-09-30$260.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0000950170-24-124698.Report this figure267Total liabilities, FY2024, at 2024-12-31$266.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-26, accession 0001193125-26-073515.Report this figure264Total liabilities, Q1 FY2025, at 2025-03-31$264.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-06, accession 0000950170-25-063971.Report this figure259Total liabilities, Q2 FY2025, at 2025-06-30$259.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-08, accession 0000950170-25-105475.Report this figure234Total liabilities, Q3 FY2025, at 2025-09-30$234.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure242Total liabilities, FY2025, at 2025-12-31$241.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure237Total liabilities, Q1 FY2026, at 2026-03-31$237.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure245Total liabilities, Q2 FY2026, at 2026-06-30$245.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure
Shareholders' equity$m(27.8)Shareholders' equity, Q3 FY2023, at 2023-09-30−$27.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0000950170-24-124698.Report this figure(34.0)Shareholders' equity, FY2023, at 2023-12-31−$34.0m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-26, accession 0001193125-26-073515.Report this figure(33.8)Shareholders' equity, Q1 FY2024, at 2024-03-31−$33.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure(37.9)Shareholders' equity, Q2 FY2024, at 2024-06-30−$37.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure(40.0)Shareholders' equity, Q3 FY2024, at 2024-09-30−$40.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure(33.7)Shareholders' equity, FY2024, at 2024-12-31−$33.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure(28.5)Shareholders' equity, Q1 FY2025, at 2025-03-31−$28.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure(27.3)Shareholders' equity, Q2 FY2025, at 2025-06-30−$27.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure14.9Shareholders' equity, Q3 FY2025, at 2025-09-30$14.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure14.3Shareholders' equity, FY2025, at 2025-12-31$14.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure9.1Shareholders' equity, Q1 FY2026, at 2026-03-31$9.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure6.9Shareholders' equity, Q2 FY2026, at 2026-06-30$6.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure

Cash flow

Operating cash flow−$2.2m, Q2 FY2026
Capital expenditure$138.0k, Q2 FY2026
Heron Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(9.2)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$9.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0000950170-24-124698. Derived: 9-month figure less the 6-month figure.Report this figure2.5Operating cash flow, Q4 FY2023, three months to 2023-12-31$2.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure(9.5)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$9.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-06, accession 0000950170-25-063971.Report this figure(4.6)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$4.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-08, accession 0000950170-25-105475. Derived: 6-month figure less the 3-month figure.Report this figure3.4Operating cash flow, Q3 FY2024, three months to 2024-09-30$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001193125-25-263618. Derived: 9-month figure less the 6-month figure.Report this figure(11.8)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$11.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure(8.9)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$8.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure(10.9)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$10.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001193125-26-341301. Derived: 6-month figure less the 3-month figure.Report this figure1.3Operating cash flow, Q3 FY2025, three months to 2025-09-30$1.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001193125-25-263618. Derived: 9-month figure less the 6-month figure.Report this figure(9.2)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$9.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure(1.5)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure(2.2)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$2.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001193125-26-341301. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.8Capital expenditure, Q3 FY2023, three months to 2023-09-30$793.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-12, accession 0000950170-24-124698. Derived: 9-month figure less the 6-month figure.Report this figure0.3Capital expenditure, Q4 FY2023, three months to 2023-12-31$250.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported0.4Capital expenditure, Q3 FY2024, three months to 2024-09-30$431.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0001193125-25-263618. Derived: 9-month figure less the 6-month figure.Report this figure0.6Capital expenditure, Q4 FY2024, three months to 2024-12-31$638.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2025, three months to 2025-03-31$109.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure0.2Capital expenditure, Q2 FY2025, three months to 2025-06-30$208.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001193125-26-341301. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0001193125-25-263618. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-073515. Derived: 12-month figure less the 9-month figure.Report this figure0.4Capital expenditure, Q1 FY2026, three months to 2026-03-31$391.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure0.1Capital expenditure, Q2 FY2026, three months to 2026-06-30$138.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001193125-26-341301. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)190.34m, Q2 FY2026
Heron Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares112Diluted shares (weighted), Q3 FY2022, three months to 2022-09-30111,735,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-14, accession 0000950170-23-063714.Report this figure119Diluted shares (weighted), Q1 FY2023, three months to 2023-03-31119,246,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-07, accession 0000950170-24-053964.Report this figure120Diluted shares (weighted), Q2 FY2023, three months to 2023-06-30119,719,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-06, accession 0000950170-24-091764.Report this figure145Diluted shares (weighted), Q3 FY2023, three months to 2023-09-30144,990,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0000950170-24-124698.Report this figure151Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31151,199,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-06, accession 0000950170-25-063971.Report this figure152Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30152,305,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-08, accession 0000950170-25-105475.Report this figure153Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30152,830,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure197Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31196,921,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure154Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30154,020,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure170Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30170,348,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-04, accession 0001193125-25-263618.Report this figure190Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31189,646,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001193125-26-215755.Report this figure190Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30190,335,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure

Shares outstanding: 189.85mShares outstanding, period not labelled, at 2026-08-05189,852,307 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-341301.Report this figure at Aug 5, 2026, from the cover of the 10-Q filed Aug 10, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. Listed shows no prices and gives no investment advice.